Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure.
Blockade of AngII (angiotensin II) and ET (endothelin)-1, established and potential therapeutic strategies respectively, for heart failure, may have an adverse effect on the cardiac secretion of the natriuretic peptides, hormones with actions beneficial in this disease. The present study investigates the roles of AngII and ET-1 in regulating the stretch-induced release of the natriuretic peptides during the development of heart failure. On seven separate days, eight sheep underwent incremental left ventricular pacing (155, 190 and 225 beats/min for 90 min each) with concurrent infusions of a vehicle control, AngII, ET-1, AngII+ET-1, losartan [AT1 (AngII type 1) receptor antagonist], bosentan (ET(A)/ET(B) receptor antagonist) or losartan+bosentan. Pacing-induced rises in LAP (left atrial pressure) were amplified by the simultaneous administration of separate AngII and ET-1, and attenuated following blockade of the peptides, with maximum effects observed during combined treatments. Although these changes in atrial pressure were paralleled by concomitant alterations in circulating levels of both ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide), the plasma natriuretic peptide/atrial pressure relationship tended to be augmented by AngII and ET-1 and diminished by their blockade. A significant difference was demonstrated between the enhanced plasma BNP response to increasing LAP during combined AngII+ET-1 administration and decreased response during losartan+bosentan treatment ( P <0.05). A similar, but non-significant, trend was evident for ANP. The present study indicates dual AngII/ET-1 blockade diminishes BNP (and to a lesser extent ANP) secretion in developing heart failure, suggesting that augmentation of the natriuretic peptide system during the combination of these therapies may be of benefit.
Rademaker
Miriam T
MT
Christchurch Cardioendocrine Research Group, Department of Medicine, The Christchurch School of Medicine, Christchurch, New Zealand. miriam.rademaker@chmeds.ac.nz
Charles
Chris J
CJ
Espiner
Eric A
EA
Frampton
Chris M
CM
Nicholls
M Gary
MG
Richards
A Mark
AM
D000804:Angiotensin II / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D000077300:Bosentan; D002302:Cardiac Output / Q000502:physiology; D002303:Cardiac Output, Low / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D002304:Cardiac Pacing, Artificial / Q000379:methods; D006152:Cyclic GMP / Q000097:blood; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D005260:Female; D007263:Infusions, Parenteral; D019808:Losartan / Q000008:administration & dosage; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D012083:Renin / Q000097:blood; D012756:Sheep; D013449:Sulfonamides / Q000008:administration & dosage
D057911:Angiotensin Receptor Antagonists; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D013449:Sulfonamides; D000804:Angiotensin II; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D012083:Renin; D006152:Cyclic GMP; D019808:Losartan; D000077300:Bosentan